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Purpose: To report our experience with a sequential regimen of induction TPF-C followed
by radioimmunotherapy with cetuximab in patients with locally advanced head and neck
squamous cell carcinoma (HNSCC).
Patients and Methods:Toxicity and outcome was retrospectively analyzed in 22 patients
receiving sequential therapy with induction TPF-C followed by radioimmunotherapy
between October 2008 and December 2011. Outcome was estimated using Kaplan–Meier
analyses. In addition, we performed mutation analysis for PIK3CA genes and high risk HPV
DNA detection using PCR.
Results: Mean time of follow-up was 16 months. Six patients were TNM Stage III, 15
patients IV (IVA or IVB), and one patient Stage II with bulky disease. During TPF-C, Grade
3 and 4 toxicities occurred in eight patients, dose modifications in seven, delays in one,
and unplanned admissions in five. Clinical tumor response was documented in 18 of the
21 patients who completed at least three cycles of TPF-C with three patients developing
complete response and 15 partial responses. Grade 3/4 mucositis was observed in six
patients. At a median follow-up of 19 months, 13 patients were alive and nine had died
including seven patients as a result of disease persistence or recurrence and two as a
result of unrelated causes. PIK3CA mutations were not identified and our two oropharynx
cases were HPV negative.
Conclusion: The combination of induction TPF-C with concurrent cetuximab radioim-
munotherapy in patients with locally advanced HNSCC is tolerable, with encouraging
efficacy.
Keywords: HNSCC,TPF-C, cetuximab radiotherapy, toxicity and outcome, mutation analysis, PIK3CA, HPV DNA
INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) is the
sixth most common cancer worldwide. Approximately 60%
of patients present with locally advanced disease (Al-Sarraf,
2002; Seiwert and Cohen, 2005). Tobacco use or/and alco-
hol consumption are implicated in the majority of cases.
High risk Human papilloma virus (HPV) infection, mainly type
16, accounts for a subset of HNSCC, particularly oropharyngeal
squamous cell carcinomas (OSCC; Gillison et al., 2000; Weinberger
et al., 2006). HPV positivity confers a 60–80% reduction in risk
of death from disease compared to similarly treated HPV negative
cancers (Gillison, 2010). Median survival time for HPV negative
patients was 21 months and not reached for HPV positive patients
in TAX324 clinical trial of sequential chemotherapy regimen (Pos-
ner et al., 2011). The 5-year progression-free (PFS) and overall
survival (OS) rates for HPV negative patients were 28 and 35%,
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respectively while PFS and OS for HPV positive patients were 78
and 82%, respectively. It seems that even with aggressive sequen-
tial therapy programs, HPV negative patients have an extremely
poor outcome. An important goal of research strategies for poor
prognosis HPV negative cancers will be optimization of treatment
regimens with the incorporation of novel active agents.
Multimodality treatment approaches including chemotherapy
and radio immunotherapy have been extensively studied (Argiris
et al., 2010; Jensen et al., 2011). A meta-analysis including more
than 17,000 patients (Pignon et al., 2009) demonstrated a 6.5%
absolute survival benefit for concurrent chemoradiotherapy and
an 11% survival benefit for concurrent cisplatin chemoradio-
therapy. Concurrent high-dose cisplatin plus radiation therapy
represents the widely accepted standard of care for patients with
stage III through IVB HNSCC (Adelstein et al., 2003; Forastiere
et al., 2003). A smaller benefit was seen in meta-analysis with
induction chemotherapy. Two phase III randomized studies tested
the incorporation of docetaxel to the standard PF induction regi-
men (Posner et al., 2007;Vermorken et al., 2007). Both studies have
demonstrated the superiority of TPF against PF in terms of PFS
and OS. TPF is considered the new standard regimen for induction
chemotherapy.
Cetuximab, a monoclonal antibody targeting the epidermal
growth factor receptor (EGFR), is an active agent in head and
neck cancer. Bonner et al. (2006, 2010) showed that cetuximab
combined with radiotherapy (RT) significantly improves locore-
gional recurrence rate, progression-free and OS compared with RT
alone in locally advanced HNSCC. Cetuximab plus RT, however,
has not been compared to the current standard, cisplatin plus RT,
in the setting of a phase III randomized trial.
The EXTREME study in recurrent/metastatic setting showed
that cetuximab combined with platinum plus 5-Fluorouracil (PF)
improves outcome measures (Vermorken et al., 2008). To increase
efficacy, TPF plus cetuximab (TPF-C) appears an appealing induc-
tion regimen. The combination of TPF-C induction chemother-
apy followed by cetuximab radioimmunotherapy in order to
maximize efficacy and reduce toxicity is appealing therapeutic
strategy.
A consistent mechanism of resistance to cetuximab has not
been described in HNSCC. Breast cancers with either activating
mutations in PIK3CA or with PTEN loss are resistant to treatment
with the Her2/Neu targeting antibody, trastuzumab (Berns et al.,
2007). Jhawer et al. (2008) also showed that PIK3CA and Ras/BRAF
mutation status may stratify colon cancer patients that may bene-
fit from cetuximab. Taken together, these data support the notion
that the mutation status of the PI3K signaling pathway should be
considered before treatment with EGFR-targeted therapy.
Here, we report our experience of treating selected fit patients
with locally advanced HNSCC with 3–4 cycles of induction with
modified TPF-C regimen followed by concurrent weekly cetux-
imab (400 mg/m2 loading dose before RT and 250 mg/m2 weekly
during the 7 weeks of RT), demonstrating the feasibility of this
approach along with encouraging evidence of efficacy. In addi-
tion, we sought to determine the incidence of PIK3CA activating
mutations in this small cohort of patients with HNSCC.
MATERIALS AND METHODS
ELIGIBILITY FOR TPF-C INDUCTION CHEMOTHERAPY
In October 2008 the Attikon Hospital approved the use of induc-
tion TPF-C chemotherapy followed by concurrent cetuximab-
based radioimmunotherapy for the management of patients with
locally advanced HNSCC (Figure 1). TPF-C consisted of docetaxel
75 mg/m2 on day 1, cisplatin 75 mg/m2 on day 1, 5-Fluorouracil
dose of 1000 mg/m2/day on days 1–4 and cetuximab 500 mg/m2 on
day 1 of 21 day chemotherapy cycle. Before treatment the records
of each patient were reviewed independently to ensure compliance
FIGURE 1 |Treatment Schema.
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with the following eligibility criteria: (1) biopsy-proven squamous
cell carcinoma of the oral cavity, oropharynx (HPV negative),
hypopharynx, larynx, or unknown primary; (2) TNM Stage II
with bulky disease, III, or IV (IVA or IVB) according to American
Joint Committee on Cancer Classification (Sobin and Compton,
2010); (3) Unresected tumor prior to chemoradiotherapy due
to technical unresectability and/or low surgical curability and/or
organ preservation (4) ECOG performance status (PS) 0–1; (5)
adequate bone marrow function; (6) adequate liver function; (7)
no prior chemotherapy or RT for HNSCC.
DATA COLLECTION
Consecutive patients treated with TPF-C chemotherapy for
HNSCC from October 2008 until December 2011 were identified
from medical records for analysis. Data were obtained from retro-
spective review of chemotherapy and RT medical records, paper
notes, and RT treatment charts.
PRETREATMENT ASSESSMENT
All patients were treated by the head and neck multidisciplinary
team, according to protocol. Within this protocol, all patients were
investigated and staged with endoscopy, biopsy, CT scan, and/or
MRI of the head and neck region, and CT of the thorax. The option
of a prophylactic gastrostomy was routinely discussed.
INDUCTION CHEMOTHERAPY
Induction chemotherapy was planned to be three to four cycles
(number of cycles at clinician discretion) of docetaxel 75 mg/m2
as a 1-h infusion on Day 1, cisplatin 75 mg/m2 as a 4-h infu-
sion on Day 1, 5-Fluorouracil 1000 mg/m2 as a continuous 24 h
infusion on Days 1–4 and cetuximab 500mg/m2 on day 1 three-
weekly. Carboplatin area under the concentration curve 5 (AUC
5) was substituted for cisplatin in patients older than 65 years of
age and in those with creatinine clearance less than 55 mL/min.
All patients were given adequate hydration and antiemetics (dex-
amethasone and 5-hydroxytryptamine-3 antagonists). All patients
were given dexamethasone to prevent docetaxel-related hyper-
sensitivity reactions, skin toxic effects and fluid retention and
prophylactic antibiotics on day 5 of each cycle for 10 days. Clinical
assessment of tumor response was made by a combination of clini-
cal and imaging (CT or MRI) assessment. Imaging assessment was
performed after the third cycle of induction chemotherapy. Tox-
icity was prospectively recorded according the National Cancer
Institute version 3.0 grading system for chemotherapy toxicity1.
A cycle could be delayed for up to 2 weeks to allow for a reduc-
tion in toxicity of grade 3 or more to a severity of grade 1 or less
(with the exception of alopecia, fatigue, and nail changes). Delays
beyond 2 weeks required discontinuation of TPF-C. Reductions
in docetaxel dose were planned for grade 3 and 4 neutrope-
nia, skin toxicity, and impaired liver function tests. Reductions
in the cisplatin dose were made for peripheral sensory/motor
neurotoxicity, ototoxicity, or renal impairment. Modifications in
the 5-fluorouracil dose were made for diarrhea and mucositis.
1National Cancer Institute. Common Toxicity Criteria manual,version 3.0: July 16,
2003. Available from: http://ctep.cancer.gov/reporting/ctc.html. Accessed July 2006.
RADIOTHERAPY
All patients were treated with three-dimensional conformal RT.
Patients were simulated supine with a thermoplastic mask for
immobilization. Planning CT images were obtained at 3 mm inter-
vals, and CT data were loaded into the ECLIPSE VARIAN treat-
ment planning system. Virtual simulation was done by using the
PROSOMA system. Prechemotherapy imaging was used to define
target volumes in line with recent guidance (Forastiere et al., 2003).
The clinical target volume included primary site and bilateral level
Ib, II, III, IV, and V lymph nodes. Retropharyngeal lymph nodes
were variably included, depending on tumor site and stage. Treat-
ment was routinely planned with a two phase conformal technique
of two lateral parallel opposed 6-MV photon fields with multiple
field-in-fields, with a matched anterior neck field. The posterior
border of the lateral photon fields was brought anterior to spinal
cord to avoid cord toxicity after 44 Gy in 22 fractions. Matched
electron fields were applied to the posterior neck. Standard doses
were 70 Gy in 35 fractions over 7 weeks, with 50 Gy in 25 fractions
over 5 weeks to the matched anterior neck. The quality assurance
procedure included portals once per week and in selected cases
in vivo dosimetry in the junction between anterior neck and lat-
eral field. RT-related toxicity was prospectively recorded using the
Radiation Therapy Oncology Group (RTOG) toxicity criteria (Cox
et al., 1995).
CONCURRENT RADIOIMMUNOTHERAPY
Concurrent radioimmunotherapy consisted of cetuximab
400 mg/m2 loading dose before RT and 250 mg/m2 weekly dur-
ing the 7 weeks of RT (70Gy). Toxicity was prospectively recorded
according to the National Cancer Institute version 3.0 grading
system for chemotherapy toxicity (see text footnote 1).
RESPONSE ASSESSMENT AND FOLLOW-UP
Patients were initially evaluated at the head and neck tumor
board where they were formally staged. Tumor response was
assessed after three cycles TPF-C and 3 months after comple-
tion of radioimmunotherapy. Evaluation of tumor response was
by clinical examination, endoscopy, and CT or MRI imaging of
the primary site and the neck; examination under anesthetic and
biopsies were performed in the event of any persistent clinical
or radiologic abnormality. Response evaluation was based on
RECIST criteria. Organ preservation was one goal of the treat-
ment but was secondary to attaining cure. Patients who developed
progressive disease after treatment or who failed to achieve at least
a partial response after the third course of therapy, if resectable,
underwent salvage surgery. Patients underwent repeat examina-
tion under anesthesia 8 weeks after CRT, at which time the primary
tumor site was examined (and biopsied if abnormal). Observa-
tion was recommended for patients with initial N+ disease who
achieved complete or partial response after chemoradiotherapy.
Patients were followed for relapse and survival.
SECOND PRIMARIES
Second primaries were defined based on the Warren and Gates
(1932) criteria. A new cancer of different histology, one of identical
histology diagnosed beyond 3 years after treatment of the primary
tumor, or one separated from the initial primary tumor by greater
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than 2 cm of clinically normal epithelium were all considered
second primaries.
MOLECULAR ANALYSIS OF TUMOR SPECIMENS
Genomic DNA extraction
Genomic DNA was extracted from 10 mm paraffin-embedded
sections of the tumor samples. Slides were microscopically exam-
ined and tumor areas were marked and carefully dissected under
microscopic observation. DNA extraction from dissected material
was performed using the EX-WAXTM Paraffin-embedded DNA
Extraction kit (Millipore, Temecula, CA, USA) according to the
manufacturer’s tissue protocol.
PIK3CA mutation detection
Sequences of PIK3CA (exons 9 and 20) were polymerase chain
reaction (PCR) amplified (using primer pairs are listed in Table 2).
PCR reactions were performed in 20µL final volume, containing
50 ng of genomic DNA, 10µl of Qiagen HotStarTaq Master Mix
Kit (Valencia, CA, USA) and 1µM of forward and reverse primers.
After 3 min of initial denaturation, the PCR mixtures were sub-
jected to 35 cycles of denaturation for 30 s at 95˚C, annealing
for 45 s at variable temperature according to the amplicon (see
Table 1) and extension for 45 s at 72˚C. A final extension period of
3 min at 72˚C was performed to complete the reaction.
Polymerase chain reaction products were then purified using
QIAquick PCR purification kit (Qiagen), sequenced on Applied
Biosystems 3730 Genetic Analyzer (Foster City, CA, USA) and ana-
lyzed by using Sequencher v 4.9 software. Results obtained were
confirmed on both sense and antisense strands.
Detection of high risk HPV DNA by PCR
Detection of high risk HPV was performed by GP5+/6+ PCR
assay on 50 ng DNA as described by de Roda Husman et al. (1995).
Detection of HPV 16+ samples was performed by E7-type 16
specific PCR as described by Jiang and Milner (2002).
Table 1 | Primers.
Target Sequence (5′-3′) Annealing
temperature
(˚C)
PIK3CA
(exon 9)
fw: GTCTTAGATTGGTTCTTTCCTGTC
re: ATGGCAAAGAACACAAAAGG
56
PIK3CA
(exon 20)
fw: TGGGGTAAAGGGAATCAAAAG
re: CCTATGCAATCGGTCTTTGC
62
High risk HPV
(GP5+ /GP6+)
fw: TTTGTTACTGTGGTAGATACTAC
re: CTTATACTAAATGTCAAATAAAAAG
40
HPV 16 E7 fw: CGGAATTCATGCATGGAGATA-
CACCTACAT
re: CGGGAAGCTTATGGTTTCTGA-
GAACAGATGG
58
Human
β-globin
fw: GGAGAACTCTGCCGTTACTGC
re: TTGGTCTCCTTAAACCTGTCTTGT
56
To check the DNA quality, the specimens were amplified with
beta-globin primers. As positive control, serial dilutions of DNA
isolated from the cervical carcinoma cell line SiHa (HPV 16 pos-
itive) were included. Reactions without template were used as
negative controls.
Polymerase chain reaction products were analyzed on a 2%
agarose gel stained with ethidium bromide and visualized by
UV-transillumination. Oligonucleotide sequences are shown in
Table 1.
STATISTICAL ANALYSIS
The response rate was expressed as the proportion of patients who
demonstrated a CR and/or PR. OS was measured from the day
of histologic diagnosis until death of any cause. Progression-free
survival (PFS) was calculated from the date of histologic diag-
nosis until date of progressive disease or death of any cause. PFS
and OS times were summarized using Kaplan–Meier product limit
curves using log-rank analysis to determine statistical significance.
All calculations and analyses were carried out with SPSS 17.0 for
Windows (SPSS Inc., Chicago, IL, USA).
RESULTS
PATIENTS AND TUMOR CHARACTERISTICS
Twenty-two patients were treated between October 2008 and
December 2011 with induction TPF-C at Attikon Hospital. The
demographic characteristics of the patients are shown in Table 2.
Mean follow-up was 16 months (range, 6–38 months). Mean age
was 55 years (range, 35–77 years). Twenty patients were male; 20
were current or ex-smokers (>10 pack years); 13 had a history of
high or moderate alcohol consumption. All patients were ECOG
PS 0 or 1. All patients had pathologically proven squamous cell
carcinoma. Tumor subsite distribution and pathologic grade are
summarized in Table 3. The TNM classification for these patients
is summarized in Table 4.
INDUCTION CHEMOTHERAPY WITH TPF-C: DELIVERY, TOXICITY, AND
CLINICAL RESPONSE
The toxicity of TPF-C is summarized in Table 5. All patients were
planned to receive 3–4 cycles of induction TPF-C chemotherapy.
Table 2 | Demographic characteristics.
Age
<65 years 4
≥65 years 18
Sex
Male 20
Female 2
Smoking
No 2
Yes 20
Etoh
No-social 9
Mild-heavy 13
Hpv status
(−) 22
(+) 0
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Table 3 | Summary of tumor subsite and histologic grade.
Parameter n (total=22)
PRIMARYTUMOR SITE
Oral cavity 8
Oropharynx 2
Larynx 7
Hypopharynx 3
Unknown primary 2
HISTOLOGIC GRADE
Well differentiated 1
Moderately differentiated 10
Poorly differentiated 7
Unclassified 4
Table 4 | Summary ofTNM distribution.
N stage 0 1 2A 2B 2C 3 Total
T stage
1 – 1 – – – – 1
2 1 1 – – 1 – 3
3 3 1 – 4 1 – 9
4 4 – – – 2 1 7
X (occult primary) – – – 1 1 2
Total 8 3 – 4 5 2 22
Table 5 | Summary of toxicity ofTPF-C chemotherapy.
Toxicity Grade 1 Grade 2 Grade 3 Grade 4
Neutropenia 3 1 3 1
Nausea/vomiting 1
Infection 1
Cardiac toxicity 1
Diarrhea 1
DVT 1
Pulmonary embolism 1
Allergic reactions 1
Transaminitis 1
Mucositis 3 1
Skin toxicity 3 3
Renal toxicity 1
However, one patient received only one cycle of TPF-C, due to
thrombosis of the jugular vein (port-a-cath insertion site) which
required prolonged hospitalization and TPF-C discontinuation.
One patient received five cycles due to individual physician pref-
erence. In three patients, cisplatin was substituted by carboplatin.
Two of them were older than 65.
Grade 3 and 4 toxicities during induction TPF-C were recorded
in 8 patients (Table 4). Delay in administration of TPF-C occurred
in one patient due to grade 4 neutropenia. Dose modifications
were made in a total of seven patients. Modifications included
omission of 5-FU for two cycles in one patient due to cardiac
Table 6 |Toxicity in administration of concurrent cetuximab
radiotherapy.
Toxicity Grade 1 Grade 2 Grade 3 Grade 4
Nausea/vomiting 1 1
Fatigue-weight loss 1 2 1
Skin toxicity 2 6 1
Mucositis 1 3 5 1
Anemia 1
ischemia, omission of day 3 and 4 of 5-FU for one cycle due to
grade 3 diarrhea in one patient, omission of docetaxel for one
cycle due to grade 3 allergic reaction in one patient and 20% dose
reductions in four patients secondary to Grade 3/4 toxicity. In one
patient cisplatin was substituted by carboplatin due to decline in
renal function.
Five unplanned admissions occurred during induction
chemotherapy with TPF-C. Duration of admission varied from
5 days to over a month. Reasons for admission included pul-
monary embolism (n= 1), febrile neutropenia (n= 1), intractable
nausea, and vomiting (n= 1), febrile thrombophlebitis of jugu-
lar vein (n= 1) and extensive tongue bleeding due to tumor
progression (n= 1).
Tumor response was assessed clinically at the end of three cycles
of induction chemotherapy. Clinical tumor response (CR or PR)
was documented in 18 of the 21 patients who completed at least
three cycles of TPF-C with three patients developing complete
response and 15 partial responses. One patient had stable dis-
ease and two patients developed disease progression. One patient
with progressive disease went on to salvage surgery (laryngectomy)
followed by RT and the other one developed extensive tongue
bleeding and was treated with RT alone.
TIME FROM COMPLETING CHEMOTHERAPY TO COMMENCING RT
Of the 21 patients who completed induction TPF-C, 19 patients
who attained at least SD with TPF-C chemotherapy went on to
receive radioimmunotherapy with cetuximab. The median time
from the administration of the final cycle of TPF-C to delivery
of the first fraction of RT was 25 days (range, 13–37 days). Four
patients began RT≤ 21 days, 3≤ 28 days, and 12≤ 35 days after
the final administration of TPF-C.
RT DELIVERY
Of the 19 patients treated with radical RT schedules, the major-
ity received 70 Gy in 35 fractions prescribed over 7 weeks. All 19
patients completed their prescribed radical RT regimen.
ADMINISTRATION OF RADIOIMMUNOTHERAPY
From the original cohort of 22 patients, 19 received radioim-
munotherapy with cetuximab. Two patients received four cycles
of concurrent cetuximab, four received five, six received six, and
seven patients received seven cycles. Four patients experienced
delays in delivery of cetuximab.
The toxicity during radioimmunotherapy with cetuximab is
summarized in Table 6. Grade 4 complications were recorded
in one patient. Non-hematologic grade 3 and 4 toxicities were
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observed in eight patients. Non-hematologic grade 3 toxicities
included nausea and vomiting, fatigue/weight loss, skin toxic-
ity, and mucositis. Hematologic grade 3 or 4 toxicity was not
encountered in any patient.
Cetuximab-related toxicity was recorded according to the NCI-
CTCAE classification system (version 3). Cetuximab-induced
skin toxicity was found in nine patients, eight of whom had
grade 1–2 skin toxicity, and 1 grade 3. RT-related toxicity was
recorded according to Acute Radiation Morbidity Scoring Cri-
teria of the RTOG. Mucosal toxicity (mucositis) was the most
common and was observed in all the patients. Grade 4 mucositis
was recorded in one patient, grade 3 in five patients, and grade
2 in five patients. One unscheduled admission for one day dur-
ing concurrent radioimmunotherapy occurred due to grade 4
mucositis.
ASSESSMENT OF RESPONSE 3MONTHS AFTER COMPLETION OF RT
Of the 19 patients who completed radical RT plus cetuximab, four
achieved complete response to treatment. Fourteen patients had
partial response and one patient had stable disease.
MUTATION ANALYSIS OF TUMOR SAMPLES
Fifteen of 22 patients had formalin fixed paraffin-embedded tissue
(FFPE) available for molecular analysis. Thirteen of 15 FFPE sam-
ples had amplifiable DNA. Mutations of PIK3CA gene within the
helical and kinase domains (exons 9 and 20) can cause constitutive
activation of PI3K and the consequent activation of AKT path-
way (Du et al., 2012). We therefore analyzed all cases for somatic
mutations within the two hotspot regions (exons 9 and 20) of
PIK3CA gene, where >80% of the reported mutations are found
(Qiu et al., 2006). However, none of cases were found to harbor
PIK3CA activating somatic mutations (data not shown). Our ret-
rospective analysis included only two oropharynx cases which were
both HPV negative.
OUTCOMES
Survival and PFS are shown in Figure 2. The 1-year OS rates are
76.7% (95% CI, 60.7–96.9%) and the 1-year PFS was 59.1% (95%
CI, 41.7–83.7%), respectively.
At a median follow-up of 19 months, 13 patients were alive and
nine had died including seven patients as a result of disease persis-
tence or recurrence and two patients as a result of unrelated causes;
one died of pneumonia 9 months after diagnosis and a second in
less than a month after treatment completion due to starvation
as a consequence of psychotic depression. The median time for
progression-free survival was 25 months. Nine patients have had
documented disease progression. The first site of progression was
locoregional in six patients. Three patients experienced treatment
failure distantly without documented locoregional failure. Of the
nine patients who relapsed, seven had a relapse in ≤12 months
and two in>12 months. One patient with local recurrence under-
went laryngectomy followed by RT and is still free of disease. One
patient with hypopharynx cancer developed tonsillar cancer as a
second primary which was managed with surgery.
DISCUSSION
The data presented here demonstrate the feasibility of induction
TPF-C followed by cetuximab-radioimmunotherapy in patients
with locally advanced HNSCC. We report that induction with a
modified TPF-C regimen followed by radioimmunotherapy with
cetuximab is a safe and active sequential therapy regimen.
Four studies have evaluated induction TPF-C in HNSCC. The
feasibility of adding cetuximab to induction TPF was first demon-
strated in a phase I study conducted at Dana Farber Cancer
Institute (Haddad et al., 2009). The primary objective of the
study was to determine the maximum tolerated dose (MTD)
of 5-Fluorouracil in TPF regimen when combined with stan-
dard dose cetuximab for induction treatment of locally advanced
FIGURE 2 | Progression-free and overall survival.
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HNSCC. Of the three 5-FU dose levels studied (750, 850, and
1000 mg/m2) 850mg/m2 daily as a continuous infusion days 1–
4 of each chemotherapy cycle was identified as the MTD. At
this dose level three of 13 patients developed a dose-limiting
toxicity (mucositis, diarrhea, febrile neutropenia). An average of
seven cetuximab doses was administered of the nine intended. All
evaluable patients attained a partial radiographic response after
induction and sixteen of twenty (80%) patients who underwent
biopsy of the primary site before the initiation of CRT developed
a pathological CR. All 28 patients went on to receive concurrent
chemo RT per treating institution practice.
A similar toxicity pattern was seen in an EORTC Phase II
study, which combined cetuximab to the European TPF regimen
(cisplatin 75 mg/m2 and docetaxel 75 mg/m2 on day 1 followed
by 5-FU 750 mg/m2/day as a continuous infusion for 5 days).
After four cycles of TPF-C, patients received cetuximab weekly
combined with concurrent chemoradiation, with either weekly
cisplatin 40 mg/m2 or weekly carboplatin AUC 1.5 mg/ml/min.
The study was terminated prematurely due to mainly gastroin-
testinal serious adverse events [Vermorken JB, Pers. Comm.]. The
DeLOS II trial is a German multicenter randomized Phase II lar-
ynx preservation study evaluating induction TPF with or without
cetuximab followed by RT (Dietz et al., 2010). The primary end
point of the trial was functional larynx preservation rate. Patients
with no response after one cycle of induction chemotherapy were
to proceed to laryngectomy. A standard TPF regimen was ini-
tially employed. However, due to five toxic deaths in the first 62
enrolled patients (4 in the TPF-alone arm), 5-Fluorouracil was
subsequently omitted from the induction regimen.
Mesia et al. (2009) conducted a phase II trial in seven Spanish
hospitals of four cycles of the European induction TPF regimen
plus cetuximab followed by cetuximab radioimmunotherapy in
patients with unresectable locally advanced-stage IV HNSCC and
PS 0–1. Induction comprised docetaxel 75 mg/m2 on day 1, cis-
platin 75 mg/m2 on day 1, 5-Fluorouracil 750 mg/m2 on days
1–5, and cetuximab 250 mg/m2 on days 1, 8, and 15 (initial dose
400 mg/m2 on cycle 1, day 1), repeated every 21 days for four
cycles with prophylactic antibiotics and G-CSF support. Subse-
quently, patients received accelerated RT with a concomitant boost
(69.9Gy) and cetuximab 250 mg/m2 weekly. Objective response
rate to TPF-C was the primary end point. G-CSF and antibiotics
were given prophylactically. Serious grade 3/4 adverse events were:
neutropenia (24%); neutropenic fever (20%), infection (6%);
thrombocytopenia (4%); diarrhea (12%); hepatotoxicity (4%);
hypomagnesemia (2%). There were two toxic deaths due to febrile
neutropenia and hepatic insufficiency. RR (CR+PR+ SD) after
four cycles of induction was 78%. Survival results have not been
reported to date.
Here, we report our experience of treating selected fit patients
with locally advanced HNSCC with induction TPF-C followed
by concurrent cetuximab-radioimmunotherapy (70Gy). We used
docetaxel 75 mg/m2, cisplatin 75 mg/m2, 5-Fluorouracil dose of
1000 mg/m2/day as a continuous infusion for 4 days and cetux-
imab 500 mg/m2 on day 1 of 21-day chemotherapy cycle. Our
sequential regimen was feasible and it showed promising activity.
No toxic deaths occurred. The main difference from the other TPF-
C regimens is that instead of standard dose cetuximab we used
500 mg/m2 on day 1 of 21-day chemotherapy cycle. This modified
dose and schedule of cetuximab resulted in reduced gastrointesti-
nal toxicity. In the aforementioned DFCI study of TPF-C, despite
reduction in 5-Fluorouracil dose level of standard TPF from 1000–
850 mg/m2, an average of seven cetuximab doses were given of nine
intended. The combination of 5-Fluorouracil with standard dose
cetuximab resulted in excessive gastrointestinal toxicity. Cetux-
imab 500 mg/m2 on day 1 of 14-day chemotherapy cycle has been
found as active as standard dose cetuximab in colon cancer. Two
randomized studies were presented at American Society of Clin-
ical Oncology Meeting in 2012 comparing concurrent chemo RT
with sequential treatment regimens. Both of them were terminated
before the planned accrual could be reached due to slow enroll-
ment (Cohen et al., 2012; Haddad et al., 2012). In both studies the
standard arms performed unexpectedly well probably due to HPV
epidemic in the United States and oropharynx cases represented
the majority of patients. The studies showed no survival difference
between standard concurrent chemo RT and sequential regimens.
The studies do not provide definitive answer concerning the value
of induction chemotherapy. Our retrospective analysis included
only two oropharynx cases which were both HPV negative.
We found no activating PIK3CA mutations in this small cohort
of HPV negative HNSCC. Our findings are consistent with data
showing that PIK3CA mutations are more common in HPV
positive HNSCC (Yarbrough et al., 2007).
To summarize, the combination of our modified induction
TPF-C regimen with concurrent cetuximab radioimmunotherapy
in patients with locally advanced head and neck squamous cell
carcinoma is tolerable, with encouraging efficacy.
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